Forte I, Indovina P, Iannuzzi C, Cirillo D, Di Marzo D, Barone D, et al. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019;54:2189-2199 pubmed publisher

Wang Z, Zhu Z, Lin Z, Luo Y, Liang Z, Zhang C, et al. miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1. Cancer Cell Int. 2019;19:115 pubmed publisher

Pishvaian M, Slack R, Jiang W, He A, Hwang J, Hankin A, et al. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 2018;124:2337-2346 pubmed publisher

Lee S, Tsai C, Yu C, Ho Y, Hsu H, Chang Y. The expression of O(6) -methylguanine-DNA methyltransferase in human oral keratinocytes stimulated with arecoline. J Oral Pathol Med. 2013;42:600-5 pubmed publisher

Giaginis C, Michailidi C, Stolakis V, Alexandrou P, Tsourouflis G, Klijanienko J, et al. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit. 2011;17:BR81-90 pubmed

Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival. J Oral Pathol Med. 2011;40:218-26 pubmed publisher